Deliverables
The product is a new rough (R) vaccine against Brucella melitensis infection of sheep. This R vaccine eliminates the diagnostic problems caused by the classical Rev 1 vaccine in the standard serological tests (rose bengal and complement fixation). A modified iELISA protocol offered as ancillary serodiagnostic tool also reduces the residual serological interference in this assay.
The R vaccine is based on the mutation of a gene selected through experiments in laboratory models and in sheep among 16 potentially interesting genes. It carries markers for easy typing and comes with a PCR typing protocol.
This R vaccine is safer than Rev 1 for humans and is not resistant to the antibiotics used to treat human brucellosis, a disadvantage of the classical Rev 1 vaccine and of previously described R vaccines.
Protection afforded by the new vaccine is much higher than that published for other R vaccines in sheep. It does not reach the levels of protection afforded by vaccine Rev 1 (58% versus 100% protection in the controlled experiment carried out) but may be an alternative prophylactic tool under special circumstances.
Searching for OpenAIRE data...
There was an error trying to search data from OpenAIRE
No results available